Research programme: histamine H3 receptor antagonists - Arena Pharmaceuticals
Latest Information Update: 21 Apr 2011
At a glance
- Originator Arena Pharmaceuticals
- Class Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Hypersomnia; Sleep disorders